APELOA(SZ:000739) 智通财经网·2025-11-24 08:08Core Viewpoint - Prolo Pharmaceutical's subsidiary has received a drug registration certificate for a new antibiotic, indicating a significant development in its product pipeline [1] Group 1: Company Developments - Prolo Pharmaceutical's wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Cefdinir Dry Suspension (1.5g; 3.0g) [1] - The newly approved Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic, aimed at treating mild to moderate infections in pediatric patients caused by specific sensitive strains of microorganisms [1] Group 2: Product Details - Cefdinir Dry Suspension is indicated for the treatment of acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae (only penicillin-sensitive strains), and Moraxella catarrhalis (including beta-lactamase producing strains) [1] - It is also indicated for pharyngitis/tonsillitis caused by Streptococcus pyogenes and uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) and Streptococcus pyogenes [1]